Farms.com Home   News

U.S. Cattle Producers Reaffirm Safety, Transparency Of Beef Supply Chain

In response to efforts in the Missouri State Legislature to regulate products sold, distributed for use, or administered to a person that are designed with intent to alter a person’s genome, the U.S. Cattlemen’s Association (USCA) issues the following statement:

“A viral tweet issued earlier this month called our attention to House Bill 1169, sponsored by Missouri state representative Holly Jones. Similar legislation is also being introduced in Tennessee, Arizona, and other states, with plans underway to attempt to implement a state-by-state regulatory framework for labeling of products that could act as a ‘gene therapy or that could possibly impact, alter or introduce genetic material or a genetic change into the user.’

“First, let us be clear. USCA strongly supports truth in labeling on consumer goods and full transparency throughout the supply chain. Accordingly, we support the underlying intent of Missouri House Bill 1169 that seeks to provide greater information to consumers.

“Currently, there are no mRNA vaccines licensed for beef cattle in the U.S. Since little is known about the technology, our organization will be forming a task force to develop a fact- and science-based assessment of the issue. We invite all members of the beef supply chain to participate in these discussions and look forward to identifying ways through legislation, regulation, or voluntary measures to increase transparency in the development and application of livestock vaccines and other gene therapies.

“Consumers deserve to know how their food is produced. USCA will continue to prioritize the safety and transparency of the beef supply chain and advocate for the health and wellbeing of its consumers, as it always has.”

Click here to see more...

Trending Video

What Successful AI Implementation Looks Like in the Protein Industry | Ben Allen, CEO of BinSentry

Video: What Successful AI Implementation Looks Like in the Protein Industry | Ben Allen, CEO of BinSentry

In this conversation, Ben Allen, CEO of BinSentry, explores what separates successful AI implementation from early experimentation across the protein industry. As producers begin integrating artificial intelligence into their operations, the most effective implementations share common themes: strong data foundations, practical use cases, and a focus on solving real operational challenges. Ben discusses why data quality and integration are essential for AI to deliver meaningful results, and why technology alone is not enough. Successful adoption also depends heavily on people, training, and company culture, ensuring teams understand how to use new tools and trust the insights they provide. Looking ahead, the conversation highlights the steps protein producers can take today—from improving data infrastructure to embracing digital tools—to position their operations for long-term success in an increasingly AI-driven industry.